ANUHPHR · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 30/100 — Quality 47 · Valuation 24 · Momentum 0
| Share price | ₹80.61 |
| Market cap | ₹790 Cr |
| P/E ratio | 19.2 |
| P/B ratio | 2.2 |
| ROE | 81.9% |
| ROCE | 15.4% |
| Dividend yield | 1.90% |
| Book value | ₹35.28 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹772 Cr | ₹41 Cr | 6.5% |
| 2025 | ₹662 Cr | ₹47 Cr | 7.9% |
| 2024 | ₹647 Cr | ₹60 Cr | 10.5% |
| 2023 | ₹527 Cr | ₹36 Cr | 8.4% |
| 2022 | — | — | — |
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, quinolones, anti-malarial, anti-gout, anti-biotic, anti-platelet, and antihistamines; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic. The company also develops products, such as coagulants, gastrointestinal, anti convulsants, and cholesterol drugs. It also exports its products. The company was incorpor